Your session is about to expire
← Back to Search
Local Anesthetic
Group 1: Block with Ropivacaine + Dexamethasone for Postoperative Pain
Phase 3
Waitlist Available
Research Sponsored by Rothman Institute Orthopaedics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 72 hours
Awards & highlights
Study Summary
This trial is testing whether adding the steroid dexamethasone to a single injection of local anesthetic improves post-operative pain scores and reduces opioid use.
Eligible Conditions
- Postoperative Pain
- Distal Radius Fracture
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 72 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~72 hours
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Postoperative pain control
Postoperative pain control #2 questionnaire
Trial Design
2Treatment groups
Active Control
Group I: Group 1: Block with Ropivacaine + DexamethasoneActive Control2 Interventions
Before surgery an ultrasound guided supraclavicular block with ropivacaine and 4 mg of dexamethasone will be administered
Group II: Group 2: Ropivacaine Block + IV DexamethasoneActive Control2 Interventions
Before surgery an ultrasound guided supraclavicular block with ropivacaine will be administered and patients will receive dexamethasone intravenously
Find a Location
Who is running the clinical trial?
Rothman Institute OrthopaedicsLead Sponsor
121 Previous Clinical Trials
21,528 Total Patients Enrolled
3 Trials studying Postoperative Pain
523 Patients Enrolled for Postoperative Pain
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any dangers associated with Group 1: Block with Ropivacaine + Dexamethasone?
"Group 1: Block with Ropivacaine + Dexamethasone has received a score of 3 for safety. This is due to the fact that Phase 3 trials have yielded some efficacy data in addition to multiple rounds of data that support safety."
Answered by AI
Share this study with friends
Copy Link
Messenger